VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

CAR-TCR Summit Europe 2021 | Selecting TCRs: understanding peptide-HLA-TCR interactions

Dolores J. Schendel, PhD, Medigene, Planegg, Germany, provides an overview of her presentation at the CAR-TCR Summit Europe 2021 and describes the tripartide interactions that take place between the peptide, human leukocyte antigen (HLA) molecule and the T-cell receptor (TCR), which largely govern the activity of TCR-engineered T (TCR-T) cell therapies. She also explains the importance of the cross-presentation process and discusses some of the key factors that must be considered when selecting TCRs for use in TCR-T cell therapies for solid tumors. This interview took place during the CAR-TCR Summit Europe 2021.